| Causes of Emotional Eating and Matched Treatment of Obesity |
34 |
| Emerging Role of AMPK in Brown and Beige Adipose Tissue (BAT): Implications for Obesity, Insulin Resistance, and Type 2 Diabetes |
26 |
| Dysfunctional Wound Healing in Diabetic Foot Ulcers: New Crossroads |
25 |
| Gender and Sex Differences in Adipose Tissue |
25 |
| Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? |
23 |
| Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes |
21 |
| Branched Chain Amino Acids in Metabolic Disease |
21 |
| Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors |
20 |
| Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes |
18 |
| Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies |
17 |
| The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes |
16 |
| Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population |
16 |
| Painful and Painless Diabetic Neuropathies: What Is the Difference? |
16 |
| Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review |
15 |
| Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities |
15 |
| Air Pollution, Oxidative Stress, and Diabetes: a Life Course Epidemiologic Perspective |
14 |
| Thiazolidinediones: the Forgotten Diabetes Medications |
14 |
| Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes? |
14 |
| Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? |
14 |
| The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update |
14 |
| Artificial Intelligence Screening for Diabetic Retinopathy: the Real-World Emerging Application |
14 |
| Sex Differences in the Burden and Complications of Diabetes |
13 |
| Family-Based Interventions Targeting Improvements in Health and Family Outcomes of Children and Adolescents with Type 1 Diabetes: a Systematic Review |
13 |
| Diabetes and HIV |
12 |
| Ethnic Disparities in Gestational Diabetes |
12 |
| Hyperglycemia During Pregnancy and Long-Term Offspring Outcomes |
12 |
| Maternal Non-glycemic Contributors to Fetal Growth in Obesity and Gestational Diabetes: Spotlight on Lipids |
12 |
| A Review of Data of Findings on Night Shift Work and the Development of DM and CVD Events: a Synthesis of the Proposed Molecular Mechanisms |
11 |
| Treatment of Diabetic Macular Edema |
11 |
| Implications of Lipids in Neonatal Body Weight and Fat Mass in Gestational Diabetic Mothers and Non-Diabetic Controls |
11 |
| Will Genetic Engineering Carry Xenotransplantation of Pig Islets to the Clinic? |
11 |
| The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps |
10 |
| Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach |
10 |
| Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D |
10 |
| Telemedicine in Complex Diabetes Management |
10 |
| Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease |
10 |
| Diabetes in South Asians: Phenotype, Clinical Presentation, and Natural History |
10 |
| Sleep in Type 1 Diabetes: Implications for Glycemic Control and Diabetes Management |
10 |
| Therapeutic Strategies for Modulating the Extracellular Matrix to Improve Pancreatic Islet Function and Survival After Transplantation |
9 |
| Transplantation of Macroencapsulated Insulin-Producing Cells |
9 |
| Vegetarian Diets and the Risk of Diabetes |
9 |
| The Beta Cell in Type 2 Diabetes |
9 |
| Identifying Prediabetes and Type 2 Diabetes in Asymptomatic Youth: Should HbA1c Be Used as a Diagnostic Approach? |
9 |
| The Impact of Childhood and Adolescent Obesity on Cardiovascular Risk in Adulthood: a Systematic Review |
9 |
| Type 2 Diabetes: Multiple Genes, Multiple Diseases |
9 |
| New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors |
9 |
| Self- and Social-Regulation in Type 1 Diabetes Management During Late Adolescence and Emerging Adulthood |
8 |
| Genetics of Severe Obesity |
8 |
| The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus |
8 |
| Neighborhood Environments and Diabetes Risk and Control |
8 |
